



(11) **EP 1 620 725 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**03.08.2011 Bulletin 2011/31**

(21) Application number: **04750577.1**

(22) Date of filing: **23.04.2004**

(51) Int Cl.:  
**G01N 33/53 (2006.01)**

(86) International application number:  
**PCT/US2004/012646**

(87) International publication number:  
**WO 2004/097412 (11.11.2004 Gazette 2004/46)**

(54) **DETECTION OF ANALYTES IN FECAL SAMPLES**

DETEKTION VON ANALYTEN IN FÄKALPROBEN

DETECTION DE SUBSTANCES A ANALYSER DANS DES ECHANTILLONS DE MATIERES FECALES

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **25.04.2003 US 424282**

(43) Date of publication of application:  
**01.02.2006 Bulletin 2006/05**

(73) Proprietor: **IDEXX LABORATORIES, INC.**  
**Westbrook, ME 04092 (US)**

(72) Inventors:  
• **TONELLI, Quentin, J.**  
**Portland, ME 04103 (US)**  
• **GROAT, Randall, G.**  
**Falmouth, ME 04105 (US)**  
• **MONN, Michael, P.**  
**Falmouth, ME 04105 (US)**

(74) Representative: **Taormino, Joseph Paul et al**  
**Hoffmann - Eitle**  
**Patent- und Rechtsanwälte**  
**Arabellastrasse 4**  
**81925 München (DE)**

(56) References cited:  
• **ABDEL-RAHMAN S M ET AL:** "Evaluation of a diagnostic monoclonal antibody-based capture enzyme-linked immunosorbent assay for detection of a 26- to 28-kd *Fasciola hepatica* coproantigen in cattle." **AMERICAN JOURNAL OF VETERINARY RESEARCH**. MAY 1998, vol. 59, no. 5, May 1998 (1998-05), pages 533-537, XP009038253 ISSN: 0002-9645

- **DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US;** March 2004 (2004-03), **MARTINEZ-MAYA JOSE JUAN ET AL:** "[Taeniosis and detection of antibodies against cysticerci among inhabitants of a rural community in Guerrero State, Mexico.]" **XP002301542 Database accession no. PREV200300526129 & SALUD PUBLICA DE MEXICO**, vol. 45, no. 2, March 2003 (2003-03), pages 84-89, ISSN: 0036-3634
- **DUMENIGO B E ET AL:** "Kinetics of antibody-based antigen detection in serum and faeces of sheep experimentally infected with *Fasciola hepatica*" **VETERINARY PARASITOLOGY**, vol. 86, no. 1, 15 September 1999 (1999-09-15), pages 23-31, **XP002301541 ISSN: 0304-4017**
- **WILLARD M D ET AL:** "Diagnosis of *Aelurostrongylus abstrusus* and *Dirofilaria immitis* infections in cats from a human shelter." **JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION**. 1 APR 1988, vol. 192, no. 7, 1 April 1988 (1988-04-01), pages 913-916, **XP009038036 ISSN: 0003-1488**
- **DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US;** January 2003 (2003-01), **DE OLIVEIRA EDWARD JOSÉ ET AL:** "[IgM-ELISA for diagnosis of schistosomiasis mansoni in low endemic areas]" **XP002301543 Database accession no. NLM12700805 & CADERNOS DE SAUDE PUBLICA / MINISTERIO DA SAUDE, FUNDACAO OSWALDO CRUZ, ESCOLA NACIONAL DE SAUDE PUBLICA**. 2003 JAN-FEB, vol. 19, no. 1, January 2003 (2003-01), pages 255-261, ISSN: 0102-311X

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 620 725 B1**

- COULAUD J P ET AL: "Albendazole: a new single dose anthelmintic. Study in 1455 patients." ACTA TROPICA. MAR 1984, vol. 41, no. 1, March 1984 (1984-03), pages 87-90, XP009039039 ISSN: 0001-706X
- CARLETON RENEE E ET AL: "Prevalence of *Dirofilaria immitis* and gastrointestinal helminths in cats euthanized at animal control agencies in northwest Georgia." VETERINARY PARASITOLOGY, vol. 119, no. 4, 6 February 2004 (2004-02-06), pages 319-326, XP001184043 ISSN: 0304-4017

**Description****FIELD OF THE INVENTION**

5 **[0001]** The invention is related to the detection of parasitic worm infections in animals. More specifically, the invention is related to a method for detecting digestive tract parasites in mammals by determining the presence of worm antigen in animal feces.

**BACKGROUND OF THE INVENTION**

10 **[0002]** Parasitic worm (helminth) infections are common in animals and, if not diagnosed and treated, can cause serious disease or death. Current methods for diagnosis of parasitic worm infections primarily involve microscopic examination of fecal samples, either directly in fecal smears or following concentration of ova and parasites by flotation in density media. These microscopic methods are time consuming and require specialized equipment. In addition, the accuracy of results of these methods is highly dependent upon the skill and expertise of the operator. Heartworm infections can be detected in blood samples using currently available tests, such as the SNAP® Heartworm Antigen Test (IDEXX Laboratories, Inc., Westbrook, ME).

15 **[0003]** Stool handling is disagreeable and hazardous. Sanitary and inoffensive procedures for processing stool are awkward and often complex. Such procedures may include weighing, centrifuging and storing, and are difficult except in a clinical laboratory equipped with a suitable apparatus, protective equipment, and a skilled technician. Therefore, any reduction in the number of steps required to perform a fecal test and any reduction in contact between test operator and the test material is desirable. Clinical laboratories have been using the immunoassay methods for the detection of various viruses, bacteria and non-helminth parasites and organisms in feces. However, there remains a need for a simple immunoassay method for the detection of a parasitic worm infection in feces.

20 **[0004]** In the American Journal of Veterinary Research May 1998, vol. 59, No. 5, pages 533-537, antibodies are used which are specific for certain coproantigens to detect worms in feces. Coproantigens are antigens produced by parasites of the gastrointestinal tract, liver or pancreas that are released in host feces. Similar disclosure is derivable from the data by BIOSIS Biosciences Information Service, Philadelphia, PA, US, March 2004, Martinez-Maya, José Juan et al., Database Accession No. PREV2003 00526129.

25 **[0005]** From the Journal of the American Veterinary Medical Association, 1 April 1988, Vol. 192, No. 7, pages 913-916, an antibody is known, whereby this is an antibody to heartworm to detect heartworm antigens in serum.

**SUMMARY OF THE INVENTION**

30 **[0006]** The invention provides for a method of detecting the presence or absence of a parasitic worm infection in an animal. The method includes contacting the soluble worm component of a fecal sample from the animal with a first antibody as defined in claim 1. The detection step may include providing a second antibody that binds to the antigen of the antigen/antibody complex, wherein the second antibody is the same as the first antibody. The first or second antibody may be attached to a label or a phase that is immiscible with the sample, such as a solid phase.

35 **[0007]** In various aspects of the invention, the disrupted parasitic worm is a heartworm, roundworm, hookworm, or whipworm.

40 **[0008]** In another aspect, the invention provides for a method of detecting the presence or absence of a parasitic worm antigen in animal feces. The method includes (a) forming a mixture comprising the soluble portion of a fecal sample and an antibody raised against the trichloroacetic acid soluble fraction of a disrupted parasitic worm as defined in claim 8 and (b) detecting whether the antibody specifically binds an antigen in the fecal sample, wherein the antigen is selected from the group consisting of a heartworm antigen, a round worm antigen a hookworm antigen and a whipworm antigen, thereby determining the presence of a parasitic worm antigen in faces wherein the disrupted parasitic worm is heartworm.

45 **[0009]** In still another aspect of the invention, the invention provides for a method of detecting whether the digestive tract of an animal is infected with a parasitic worm. The method includes immobilizing a heartworm antibody on a solid phase, adding a soluble portion of a fecal sample from the animal to the solid phase, and detecting the binding of a parasitic worm antigen to the immobilized antibody. The detecting of the binding of the parasitic worm antigen to the immobilized antibody may include contacting the solid phase with a heartworm antibody conjugated to a label. The method may also include adding a heartworm antigen conjugated to a label to the solid phase after the addition of the soluble portion of the fecal sample and determining the presence, absence or amount of the binding of the labeled antigen to the antibody.

50 **[0010]** In yet another aspect, the invention provides for a method of detecting the presence or absence of an intestinal parasitic worm infection. The method includes:

- (a) providing a lateral flow immunoassay device having a solid phase;  
 (b) providing a first antibody raised against a heartworm antigen;  
 (c) immobilizing the first antibody on the solid phase of the immunoassay device;  
 (d) providing a second, labeled antibody;  
 5 (e) providing a soluble fraction of a fecal sample;  
 (f) contacting the soluble fraction of the fecal sample with the second, labeled antibody;  
 (g) allowing the soluble fraction of the fecal sample and the second, labeled antibody to flow along the immunoassay device towards the immobilized first antibody; and  
 10 (h) determining the presence or absence of an intestinal parasite by observing a signal in the vicinity of the first, immobilized antibody.

### DETAILED DESCRIPTION

15 **[0011]** The invention provides for a method of testing for a parasitic worm infection of the digestive tract of an animal. Detection of the infection is accomplished by detecting the binding of a soluble worm antigen present in an animal fecal sample to a worm antibody, as defined above.

20 **[0012]** Parasitic worms that are detectable using the invention include heartworms, roundworms, whipworms, and hookworms. Soluble worm antigen is any worm component present in the soluble fraction of a fecal sample that can specifically and stably bind to a worm antibody. The presence of the antigen in animal feces indicates that the digestive tract of the animal is infected with a parasitic worm.

25 **[0013]** Antibodies to worm antigen, such as a worm polyclonal antibody, can be prepared by administering to a vertebrate, such as, for example, a rabbit or chicken, the trichloroacetic acid (TCA) soluble fraction of a disrupted parasitic worm. Serum or eggs from the immunized animal are collected. Antibodies are purified from the plasma or eggs by, for example, precipitation with ammonium sulfate, followed by chromatography, such as affinity chromatography. Techniques  
 30 for producing and processing a polyclonal antibody are known in the art.

**[0014]** In one aspect of the invention, the worm antibody is an antibody raised against a heartworm antigen thereby creating a heartworm antibody. Heartworm disease is caused by the filarial nematode *Dirofilaria Immitis* (*D. immitis*) and has worldwide distribution. Adult heartworms inhabit the blood and vascular tissue of mammals, including, for example, dogs, especially in the heart and adjacent blood vessels. *D. immitis* often interferes with heart functions and  
 35 blood circulation and can damage other vital organs.

**[0015]** It has been found that the heartworm antibody can be used to detect soluble antigen of other species of worm in fecal samples. Similarly, it is expected that antibodies raised against the trichloroacetic acid fraction of other disrupted parasitic worms can be used to detect antigen of various other worm species in fecal samples.

40 **[0016]** Feces of any animal can be tested. Samples may be collected by any readily available means. Samples should be kept refrigerated until testing.

**[0017]** The worm antigen is found in the soluble portion of fecal samples. Fecal samples can be prepared by any means known in the art. In one aspect, the sample is swabbed using a collection device using a "Snap-Valve" available from Medical Packaging Corporation, Camarillo, California, as described in U.S. Patent No. 5,266,266.

45 Briefly, the sample collection device includes a hollow swab shaft extending between a fibrous swab tip and a housing base defining a reagent chamber with a liquid reagent contained therein. The swab member may be manipulated quickly and easily while holding the base to collect a fecal specimen on the fibrous swab tip. The swab is placed in a specimen chamber. A break-off nib on a rear end of the swab shaft member permits reagent delivery from the reagent chamber through a hollow swab shaft to contact the specimen on the swab tip.

**[0018]** The break-off nib is disposed within the reagent chamber and normally prevents reagent flow into the swab shaft. Deformation of the housing base is effective to sever the nib from the swab shaft at a preformed score to open the rear end of the swab shaft and permit reagent flow from the reagent chamber through the swab shaft to the swab tip.

50 **[0019]** Fecal sample on the swab tip can thus be solubilized in the specimen chamber. In one aspect, the housing is flexible, such as on the end of an eye dropper, so that the liquid reagent can be drawn up through the hollow shaft of the swab by suction created by the housing. By repeatedly expelling from, and drawing liquid into, the hollow shaft and housing, the liquid reagents can be thoroughly mixed with the fecal sample collected on the fibrous tip of the swab. In addition, the swab tip functions as a filter such that most solid fecal matter is not drawn into the shaft.

**[0020]** In addition, preparation of the fecal sample can be accomplished using any of the known methods in the art. For example the soluble portion of the sample can be collected using filtration, centrifugation, or simple mixing followed by gravimetric settling.

55 **[0021]** When antibodies raised against heartworm antigen are used in the method of present invention, there is a possibility that a test subject having heartworm infection, but no fecal parasitic infection, will have heartworm antigen in the soluble portion of a fecal sample. This can be due to antigen transfer into the digestive track through internal bleeding or other means. A second heartworm antigen test on a blood sample could be performed if the fecal sample is positive.

A heartworm negative blood test would confirm fecal parasites. Alternatively, the blood sample can be tested first, followed by a fecal test if the blood sample is negative for heartworm antigen. A positive on either test would indicate parasitic worm infection.

5 [0022] In one aspect, the antibodies of the invention are antibody molecules that specifically and stably bind to a *D. immitis* antigen. This antibodies are obtained by immunizing a vertebrate with antigen. This antigen can be prepared by disrupting worms in an aqueous buffer solution, centrifuging to remove insoluble and particulate components, adding of trichloroacetic acid to a concentration of 15% w/v, centrifuging to remove insoluble components, dialyzing against an aqueous buffer solution and lyophilizing. This preparation is used to produce antibodies in mammals using standard methods (see, e.g., Harlow, E. and D. Lane, 1988, "Antibodies: A Laboratory manual", Cold Spring Harbor Laboratory, Cod Spring Harbor, New York, USA, ISBN 0-87969-314-2 pp 92-286).

10 [0023] An antibody or fragments thereof can be a polyclonal antibody, a monoclonal antibody, a single chain antibody (scFv), a chimeric antibody, or a fragment of an antibody. Fragments of antibodies are a portion of an intact antibody comprising the antigen binding site or variable region of an intact antibody, wherein the portion is free of the constant heavy chain domains of the Fc region of the intact antibody. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')<sub>2</sub> and F<sub>v</sub> fragments.

15 [0024] An antibody of the invention can be any antibody class, including for example, IgG, IgM, IgA, IgD and IgE. An antibody can be made *in vivo* in suitable laboratory animals or *in vitro* using recombinant DNA techniques. Means for preparing and characterizing antibodies are well know in the art. See, e.g., Dean, Methods Mol. Biol. 80:23-37 (1998); Dean, Methods Mol. Biol. 32:361-79 (1994); Baileg, Methods Mol. Biol. 32:381-88 (1994); Gullick, Methods Mol. Biol. 32:389-99 (1994); Drenckhahn et al. Methods Cell. Biol. 37:7-56 (1993); Morrison, Ann. Rev. Immunol. 10:239-65 (1992); Wright et al. Crit. Rev. Immunol. 12:125-68(1992). For example, polyclonal antibodies can be produced by administering a polypeptide specific for *D. immitis* to an animal, such as a human or other primate, mouse, rat, rabbit, guinea pig, goat, pig, cow, sheep, donkey, chicken, or horse.

20 [0025] Once the antibodies of the invention have been prepared, the detection of parasitic worm in fecal samples can be accomplished using any readily available method known to those of skill in the art, for example, ELISA, western blot, immuno-fluorescent assay, radio-immuno assay, fluorescent polarization immunoassay and reversible flow chromatographic binding assay procedures. Methods and devices of the invention facilitate sandwich or competition-type specific binding assays. In the case of a sandwich assay, analyte capture reagents are immobilized in a reactive zone. Following binding of the sample analyte, the complex is reacted with labeled specific binding reagents (e.g., an enzyme-antibody conjugate) and analyte detected (e.g., upon reaction with substrate). In the case of a competition assay, analyte capture reagents are immobilized at the reactive zone and are contacted simultaneously with sample analyte and labeled analyte (e.g., an analyte-enzyme conjugate). The amount of label detected at the reactive zone is inversely proportional to the amount of analyte in the sample.

25 [0026] In one aspect, the invention includes a device for detecting the presence of a parasitic worm infection in an animal. The device includes an antibody or fragment thereof that specifically binds a worm antigen, for example, a *D. immitis* antigen, immobilized on a solid support at a distinct location. Detection of immunocomplexes on the solid support can be by any means known in the art.

30 [0027] Immobilization of one or more analyte capture reagents onto a device or solid support is performed so that an analyte capture reagent will not be washed away by wash procedures, and so that its binding to analytes in a test sample is unimpeded by the solid support or device surface. One or more analyte capture reagents can be attached to a surface by physical adsorption (i.e., without the use of chemical linkers) or by chemical binding (i.e., with the use of chemical linkers). Chemical binding can generate stronger attachment of specific binding substances on a surface and provide defined orientation and conformation of the surface-bound molecules.

35 [0028] Another embodiment of the invention provides a device that is suitable for a lateral flow assay. For example, a test sample is added to a flow matrix at a first region (a sample application zone). The test sample is carried in a fluid flow path by capillary action to a second region of the flow matrix where a particulate label capable of binding and forming a first complex with an analyte in the test sample. The particulate label can be a colored latex particle, dye sol, or gold sol conjugated to, for example, an antibody specific for a worm antigen. The first complex is carried to a third region of the flow matrix where an antibody that specifically binds a worm antigen is immobilized at a distinct location. A second complex is formed between an immobilized antibody or a polypeptide and a first complex. For example, a first complex comprising a gold sol particle and antibody specific for a worm antigen will specifically bind and form a second complex with an immobilized antibody specific for worm. The particulate label that is part of the second complex can be directly visualized.

40 [0029] In another aspect, the invention includes one or more labeled specific binding reagents that can be mixed with a test sample prior to application to a device for of the invention. In this case it is not necessary to have labeled specific binding reagents deposited and dried on a specific binding reagent pad in the device. A labeled specific binding reagent, whether added to a test sample or pre-deposited on the device, can be for example, a labeled antibody specific for *D. immitis*. For example, a *D. immitis*-specific antibody raised in a chicken conjugated with horseradish peroxidase can be

used as a labeled specific binding reagent.

**[0030]** Any or all of the above embodiments can be provided as a kit. In one particular example, such a kit would include a device complete with specific binding reagents (*e.g.*, a non-immobilized labeled specific binding reagent and an immobilized analyte capture reagent) and wash reagent, as well as detector reagent and positive and negative control reagents, if desired or appropriate. In addition, other additives can be included, such as stabilizers, buffers, and the like. The relative amounts of the various reagents can be varied, to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay. Particularly, the reagents can be provided as dry powders, usually lyophilized, which on dissolution will provide for a reagent solution having the appropriate concentrations for combining with a sample.

**[0031]** U.S. Patent No. 5,726,010, describes an example of a lateral flow device useful in the present invention. A worm antibody can be an immobilized analyte capture reagent in a reaction zone (solid phase). A second analyte capture reagent, *i.e.* a second worm antibody, that has been conjugated to a label, can either be added to the sample before the sample is added to the device, or the second analyte capture reagent can be incorporated into the device. For example the labeled specific binding reagent can be deposited and dried on a fluid flow path that provides fluid communication between the sample application zone and the solid phase. Contact of the labeled specific binding reagent with the fluid sample results in dissolution of the labeled specific binding reagent.

**[0032]** The device may also include a liquid reagent that transports unbound material (*e.g.*, unreacted fluid sample and unbound specific binding reagents) away from the reaction zone (solid phase). A liquid reagent can be a wash reagent and serve only to remove unbound material from the reaction zone, or it can include a detector reagent and serve to both remove unbound material and facilitate analyte detection. For example, in the case of a specific binding reagent conjugated to an enzyme, the detector reagent includes a substrate that produces a detectable signal upon reaction with the enzyme-antibody conjugate at the reactive zone. In the case of a labeled specific binding reagent conjugated to a radioactive, fluorescent, or light-absorbing molecule, the detector reagent acts merely as a wash solution facilitating detection of complex formation at the reactive zone by washing away unbound labeled reagent.

**[0033]** Two or more liquid reagents can be present in a device, for example, a device can comprise a liquid reagent that acts as a wash reagent and a liquid reagent that acts as a detector reagent and facilitates analyte detection.

**[0034]** A liquid reagent can further include a limited quantity of an "inhibitor", *i.e.*, a substance that blocks the development of the detectable end product. A limited quantity is an amount of inhibitor sufficient to block end product development until most or all excess, unbound material is transported away from the second region, at which time detectable end product is produced.

**[0035]** To ensure proper operation, any of the devices described herein can further include various binding reagents immobilized at locations distinct from the analyte capture reagent(s). For example, an immunoreagent that recognizes a species-specific (*e.g.*, canine specific) antibody portion of a labeled specific binding reagent or an enzyme portion of an enzyme-labeled reagent can be included as a positive control to assess the viability of the reagents within the device. For example, a positive control can comprise an anti-horseradish peroxidase antibody that has been raised in, for example, a goat or a mouse. Additionally, a reagent, *e.g.*, an antibody isolated from a non-immune member of the species from which the antibody portion of the enzyme-antibody conjugate was derived can be included as a negative control to assess the specificity of immunocomplex formation.

#### Example

**[0036]** SNAP<sup>®</sup> device technology (IDEXX Laboratories, Inc., Westbrook, ME, USA) was used to provide a solid phase with reversible, chromatographic flow of sample, and automatic, sequential flow of wash and enzyme substrate solutions as described in U.S. Patent 5,726,010.

**[0037]** Reagent Specifics. An antibody reagent raised to heartworm antigen was deposited to form a sample spot on the solid phase of the SNAP<sup>®</sup> device. A negative control reagent was deposited to form a negative control spot and a positive control reagent was deposited to form a positive control spot on the solid phase of the SNAP<sup>®</sup> device. An antibody reagent raised to *D. immitis* worm antigen was chemically conjugated to the enzyme horseradish peroxidase and provided in a solution consisting of a buffer, detergent, and animal serum components.

**[0038]** Fresh, unpreserved canine fecal samples were collected at a commercial kennel. Samples were stored refrigerated until testing.

**[0039]** Fecal material was sampled with a swab, mixed with the antibody-enzyme conjugate solution, and applied to the SNAP<sup>®</sup> device. Following a short incubation period, the device was activated and color developed on the sample spots to provide the test result. Color development on the positive control spot indicated the test was valid. Color development on the sample spot greater than color development on the negative control Spot indicated the presence of worm antigen in the fecal sample and was scored as a positive test result.

**[0040]** Reference Test Method - Fecal Flotation / Microscopic Examination. A sucrose flotation solution (specific gravity = 1.27) was used to concentrate ova and parasites for microscopic examination. A fecal sample of 0.5 - 3.0 g

**EP 1 620 725 B1**

was added to 5 ml of flotation solution and mixed thoroughly. Flotation solution was added to form a meniscus, and ova and parasites were collected on a glass cover slip for 15 - 45 minutes. The cover slip was then removed, placed on a glass slide, and examined using an Olympus CH-2 light microscope (Olympus Optical Co., Ltd., Tokyo, Japan). Ova and parasites were identified by size and morphology.

5 **[0041]** SNAP<sup>®</sup> test results and reference test results for 32 canine fecal samples are given in Table 1. Twenty five samples were positive for the presence of parasitic worms by the microscopic examination reference test method. Twenty of these samples (80%) were positive for worm antigen using the SNAP<sup>®</sup> immunoassay. Positive samples by both methods included samples containing roundworms, hookworms, and whipworms. Seven samples were negative for parasitic worms by microscopic examination and six of these (85%) were also negative for worm antigen by the SNAP<sup>®</sup> immunoassay. Resolution of the true parasitic worm status for the six samples giving discrepant results between test methods was not pursued.

10 **[0042]** Although various specific embodiments of the present invention have been described herein, it is to be understood that the invention is not limited to those precise embodiments and that various changes or modifications can be affected therein by one skilled in the art without departing from the scope of the appended claims.

15

Table 1

Sample	Microscopic Examination		SNAP <sup>®</sup> Device Immunoassay Result (Visual Examination)
	Result	Parasitic Worms Identified	
37172	Positive	roundworms	Negative
36986	Positive	hookworms, whipworms	Positive
36814	Positive	whipworms	Negative
37164	Positive	roundworms, hookworms	Positive
37174	Positive	hookworms	Positive
38000	Positive	hookworms	Positive
37138	Positive	hookworms, whipworms	Positive
37186	Positive	hookworms	Positive
37168	Positive	hookworms	Positive
37034	Positive	whipworms	Positive
36707	Positive	roundworms	Positive
37159	Positive	hookworms	Positive
36449	Positive	roundworms	Positive
36528	Negative	none detected	Negative
37100	Negative	none detected	Positive
36438	Negative	none detected	Negative
36409	Negative	none detected	Negative
36206	Positive	hookworms	Positive
37311	Positive	hookworms, whipworms	Positive
37327	Positive	roundworms, hookworms	Positive
37406	Positive	roundworms, hookworms	Positive
37522	Positive	roundworms	Positive
37549	Positive	hookworms	Negative
37532	Positive	hookworms	Negative
37241	Positive	hookworms, whipworms	Positive
37330	Positive	roundworms	Positive

(continued)

Sample	Microscopic Examination		SNAP® Device Immunoassay Result (Visual Examination)
	Result	Parasitic Worms Identified	
37331	Positive	roundworms	Positive
37427	Positive	roundworms, hookworms	Positive
37524	Positive	hookworms, whipworms	Negative
37464	Negative	none detected	Negative
36283	Negative	none detected	Negative
37173	Negative	none detected	Negative

### Claims

1. A method for detecting the presence or absence of a parasitic worm infection in an animal comprising: contacting the soluble worm component of a fecal sample from the animal with a first antibody raised against the trichloroacetic acid soluble fraction of a disrupted parasitic worm, wherein the first antibody binds a heartworm antigen, a roundworm antigen, a hookworm antigen, and a whipworm antigen; and detecting the presence or absence of an antigen/antibody complex thereby determining the presence or absence of a parasitic worm infection in the animal, wherein the disrupted parasitic worm is a heartworm, and wherein the parasitic worm infection is caused by heartworm, roundworm, hookworm or whipworm.
2. The method of claim 1 wherein the step of detecting further comprises providing a second antibody that binds to the antigen of the antigen/antibody complex, wherein the second antibody is raised against the trichloroacetic acid soluble fraction of said disrupted parasitic worm.
3. The method of claim 1 wherein the animal is canine or feline.
4. The method of claim 2, wherein the first or second antibody is attached to a phase that is immiscible with the sample.
5. The method of claim 4, wherein the phase is a solid phase.
6. The method of claim 2 wherein the first or second antibody is bound to a label.
7. The method of claim 6 wherein the label is an enzyme, a colloidal particle, a radionuclide or a fluorophore.
8. A method for detecting the presence or absence of a parasitic worm antigen in animal feces comprising: (a) forming a mixture comprising the soluble portion of a fecal sample and an antibody raised against the trichloroacetic acid soluble fraction of a disrupted parasitic worm, wherein the antibody binds a heartworm antigen, a roundworm antigen, a hookworm antigen, and a whipworm antigen; (b) detecting whether the antibody specifically binds an antigen in the fecal sample, wherein the antigen is selected from the group consisting of a heartworm antigen, a roundworm antigen, a hookworm antigen, and a whipworm antigen, thereby determining the presence of a parasitic worm antigen in feces wherein the disrupted parasitic worm is heartworm.
9. The method of claim 8, wherein the antibody is attached to a phase that is immiscible with the sample.
10. The method of claim 9, wherein the phase is a solid phase.
11. The method of claim 8, wherein the antibody is bound to a detectable moiety.
12. The method of claim 11, wherein the detectable moiety is an enzyme, a colloidal particle, a radionuclide or a fluorophore.
13. A method for detecting whether the digestive tract of an animal is infected with roundworms, hookworms, or whip-

worms comprising: immobilizing antibody raised against the trichloroacetic acid soluble fraction of a disrupted heartworm on a solid phase, wherein the antibody binds to a roundworm antigen, a hookworm antigen, and a whipworm antigen; adding a soluble portion of a fecal sample from the animal to the solid phase; detecting the binding of a parasitic worm antigen to the immobilized antibody, wherein the parasitic worm antigen is one or more of a roundworm antigen, a hookworm antigen, or a whipworm antigen, thereby detecting whether the animal is infected with a parasitic worm.

14. The method of claim 13, wherein the detecting the binding of the parasitic worm antigen to the immobilized antibody comprises contacting the solid phase with a heartworm antibody conjugated to a label.

15. The method of claim 13, further comprising adding a heartworm antigen conjugated to a label to the soluble portion of a fecal sample from the animal prior addition to the solid phase of the soluble portion of the fecal sample and determining the presence, absence or amount of the binding of the labeled antigen to the antibody.

16. The method of claim 13, further comprising testing a blood sample from the mammal to detect the presence or absence of heartworm antigen in the blood sample.

17. A method for detecting the presence or absence of an intestinal parasitic worm infection comprising: (a) providing a lateral flow immunoassay device having a solid phase; (b) providing a first antibody raised against the trichloroacetic acid soluble fraction of a disrupted heartworm; (c) immobilizing the first antibody on the solid phase of the immunoassay device; (d) providing a second, labeled antibody; (e) providing a soluble fraction of a fecal sample; (f) contacting the soluble fraction of the fecal sample with the second, labeled antibody; (g) allowing the soluble fraction of the fecal sample and the second, labeled antibody to flow along the immunoassay device towards the immobilized first antibody; and (h) determining the presence or absence of an intestinal parasite selected from heartworm, round worm, hookworm or whipworm by observing the presence or absence of a signal in the vicinity of the first, immobilized antibody.

18. A method for detecting the presence or absence of an intestinal parasitic worm infection selected from heartworm, roundworm, hookworm or whipworm in an animal comprising: (a) running a blood sample from the animal on a heartworm antigen detection device to determine the presence or absence of heartworm antigen in the blood sample; and (b) if the blood sample is negative for the presence of heartworm antigen, running a fecal sample from the same animal on a parasitic worm antigen detection device to determine the presence or absence of parasitic worm antigen in the fecal sample.

### Patentansprüche

1. Verfahren zum Nachweis der An- oder Abwesenheit einer parasitischen Wurminfektion in einem Tier, umfassend: Kontaktieren der löslichen Wurmkomponente einer Fäkalprobe von dem Tier mit einem ersten Antikörper, der gegen die Trichloressigsäure-lösliche Fraktion eines zerstörten parasitischen Wurms gerichtet ist, wobei der erste Antikörper ein Herzworm-Antigen, ein Spulwurm-Antigen, ein Hakenwurm-Antigen und ein Peitschenwurm-Antigen bindet; und Bestimmung der An- oder Abwesenheit einer parasitischen Wurminfektion in dem Tier mittels Nachweis der An- oder Abwesenheit eines Antigen/Antikörper-Komplexes, wobei der zerstörte parasitische Wurm ein Herzworm ist und wobei die parasitische Wurminfektion durch Herzworm, Spulwurm, Hakenwurm oder Peitschenwurm hervorgerufen ist.

2. Verfahren gemäß Anspruch 1, wobei der Nachweisschritt weiterhin die Bereitstellung eines zweiten Antikörpers umfasst, der an das Antigen des Antigen/Antikörper-Komplexes bindet, wobei der zweite Antikörper gegen die Trichloressigsäure-lösliche Fraktion des zerstörten parasitischen Wurms gerichtet ist.

3. Verfahren gemäß Anspruch 1, wobei das Tier Hunde- oder Katzen-artig ist.

4. Verfahren gemäß Anspruch 2, wobei der erste oder der zweite Antikörper einer Phase beigefügt ist, die nicht mit der Probe mischbar ist.

5. Verfahren gemäß Anspruch 4, wobei die Phase eine feste Phase ist.

6. Verfahren gemäß Anspruch 2, wobei der erste oder der zweite Antikörper an ein Label gebunden ist.

## EP 1 620 725 B1

7. Verfahren gemäß Anspruch 6, wobei das Label ein Enzym, ein Kolloidpartikel, ein Radionuklid oder ein Fluorophor ist.
8. Verfahren zum Nachweis der An- oder Abwesenheit eines parasitischen Wurm-Antigens in tierischen Fäkalien, umfassend: (a) Bildung einer Mischung, umfassend den löslichen Teil einer Fäkalprobe und einen Antikörper, der gegen die Trichloressigsäure-lösliche Fraktion eines zerstörten parasitischen Wurms gerichtet ist, wobei der Antikörper ein Herzwurm-Antigen, ein Spulwurm-Antigen, ein Hakenwurm-Antigen und ein Peitschenwurm-Antigen bindet; (b) Nachweis, ob der Antikörper spezifisch ein Antigen in der Fäkalprobe bindet, wobei das Antigen ausgewählt ist aus der Gruppe bestehend aus einem Herzwurm-Antigen, einem Spulwurm-Antigen, einem Hakenwurm-Antigen und einem Peitschenwurm-Antigen, und damit Feststellung der Anwesenheit eines parasitischen Wurm-Antigens in Fäkalien, wobei der zerstörte parasitische Wurm ein Herzwurm ist.
9. Verfahren gemäß Anspruch 8, wobei der Antikörper einer Phase beigefügt ist, die nicht mit der Probe mischbar ist.
10. Verfahren gemäß Anspruch 9, wobei die Phase eine feste Phase ist.
11. Verfahren gemäß Anspruch 8, wobei der Antikörper an eine nachweisbare Gruppe gebunden ist.
12. Verfahren gemäß Anspruch 11, wobei die nachweisbare Gruppe ein Enzym, ein Kolloidpartikel, ein Radionuklid oder ein Fluorophor ist.
13. Verfahren zum Nachweis, ob der Verdauungstrakt eines Tiers mit Rundwürmern, Hakenwürmern oder Peitschenwürmern infiziert ist, umfassend: Immobilisierung eines Antikörpers, der gegen die Trichloressigsäure-lösliche Fraktion eines zerstörten Herzwurms gerichtet ist, an einer festen Phase, wobei der Antikörper an ein Spulwurm-Antigen, ein Hakenwurm-Antigen und ein Peitschenwurm-Antigen bindet; Zugabe eines löslichen Teils einer Fäkalprobe von dem Tier zu der festen Phase; Nachweis der Bindung eines parasitischen Wurm-Antigens an den immobilisierten Antikörper, wobei das parasitische Wurm-Antigen eines oder mehrere von einem Spulwurm-Antigen, einem Hakenwurm-Antigen oder einem Peitschenwurm-Antigen ist, und damit Nachweis, ob das Tier mit einem parasitischen Wurm infiziert ist.
14. Verfahren gemäß Anspruch 13, wobei der Nachweis der Bindung des parasitischen Wurm-Antigens an den immobilisierten Antikörper umfasst, die feste Phase mit einem Herzwurm-Antikörper, der an ein Label konjugiert ist, zu kontaktieren.
15. Verfahren gemäß Anspruch 13, weiterhin umfassend die Zugabe eines an ein Label konjugierten Herzwurm-Antigens zu dem löslichen Teil einer Fäkalprobe von dem Tier vor der Zugabe des löslichen Teils der Fäkalprobe zu der festen Phase und Bestimmung der Anwesenheit, der Abwesenheit oder des Umfangs der Bindung des markierten Antigens an den Antikörper.
16. Verfahren gemäß Anspruch 13, weiterhin umfassend die Untersuchung einer Blutprobe von dem Säuger, um die An- oder Abwesenheit von Herzwurm-Antigen in der Blutprobe nachzuweisen.
17. Verfahren zum Nachweis der An- oder Abwesenheit einer intestinalen parasitischen Wurminfektion, umfassend: (a) Bereitstellung einer Lateral-Flow-Immunoassay-Anordnung mit einer festen Phase; (b) Bereitstellung eines ersten Antikörpers, der gegen die Trichloressigsäure-lösliche Fraktion eines zerstörten Herzwurms gerichtet ist; (c) Immobilisierung des ersten Antikörpers an der festen Phase der Immunoassay-Anordnung; (d) Bereitstellung eines zweiten markierten Antikörpers; (e) Bereitstellung einer löslichen Fraktion einer Fäkalprobe; (f) Kontaktieren der löslichen Fraktion der Fäkalprobe mit dem zweiten, markierten Antikörper; (g) Ermöglichung der Bewegung der löslichen Fraktion der Fäkalprobe und des zweiten, markierten Antikörpers entlang der Immunoassay-Anordnung in Richtung des immobilisierten, ersten Antikörpers und (h) Bestimmung der An- oder Abwesenheit eines intestinalen Parasiten, ausgewählt aus Herzwurm, Spulwurm, Hakenwurm oder Peitschenwurm, mittels Beobachtung der An- oder Abwesenheit eines Signals in der Umgebung des ersten, immobilisierten Antikörpers.
18. Verfahren zum Nachweis der An- oder Abwesenheit einer intestinalen parasitischen Wurminfektion, ausgewählt aus Herzwurm, Spulwurm, Hakenwurm oder Peitschenwurm, in einem Tier, umfassend: (a) Laufenlassen einer Blutprobe von dem Tier auf einer Herzwurm-Antigen-Nachweisanordnung, um die An- oder Abwesenheit von Herzwurm-Antigen in der Blutprobe zu bestimmen, und (b) falls die Blutprobe negativ für die Anwesenheit von Herzwurm-Antigen ist, Laufenlassen einer Fäkalprobe von demselben Tier auf einer parasitischen Wurm-Antigen-Nachweisanordnung, um die An- oder Abwesenheit von parasitischem Wurm-Antigen in der Fäkalprobe zu bestimmen.

**Revendications**

- 5 1. Procédé pour détecter la présence ou l'absence d'une infection par un ver parasite chez un animal comprenant : la mise en contact du composant de ver soluble d'un échantillon de selles de l'animal avec un premier anticorps dirigé contre la fraction soluble dans l'acide trichloroacétique d'un ver parasite détruit, dans lequel le premier anticorps se lie à un antigène de filaire des chiens, un antigène d'ascaris, un antigène d'ankylostome, et un antigène de trichure ; et la détection de la présence ou l'absence d'un complexe antigène/anticorps déterminant ainsi la présence ou l'absence d'une infection par un ver parasite chez l'animal, dans lequel le ver parasite détruit est une filaire des chiens, et dans lequel l'infection par un ver parasite est causée par une filaire des chiens, un ascaris, un ankylostome ou un trichure.  
10
2. Procédé selon la revendication 1, dans lequel l'étape de détection comprend en outre la fourniture d'un deuxième anticorps qui se lie à l'antigène du complexe antigène/anticorps, dans lequel le deuxième anticorps est dirigé contre la fraction soluble dans l'acide trichloroacétique dudit ver parasite détruit.  
15
3. Procédé selon la revendication 1, dans lequel l'animal est canin ou félin.
4. Procédé selon la revendication 2, dans lequel le premier ou le deuxième anticorps est fixé sur une phase qui est non miscible à l'échantillon.  
20
5. Procédé selon la revendication 4, dans lequel la phase est une phase solide.
6. Procédé selon la revendication 2, dans lequel le premier ou le deuxième anticorps est lié à une marque.
- 25 7. Procédé selon la revendication 6, dans lequel la marque est une enzyme, une particule colloïdale, un radionucléide ou un fluorophore.
8. Procédé pour détecter la présence ou l'absence d'un antigène de ver parasite dans les fèces d'un animal comprenant : (a) la formation d'un mélange comprenant la partie soluble d'un échantillon de selles et un anticorps dirigé contre la fraction soluble dans l'acide trichloroacétique d'un ver parasite détruit, dans lequel l'anticorps se lie à un antigène de filaire des chiens, un antigène d'ascaris, un antigène d'ankylostome, et un antigène de trichure ; (b) la détection si l'anticorps se lie spécifiquement à un antigène dans l'échantillon de selles, dans lequel l'antigène est choisi dans le groupe constitué d'un antigène de filaire des chiens, d'un antigène d'ascaris, d'un antigène d'ankylostome, et d'un antigène de trichure, déterminant ainsi la présence d'un antigène de ver parasite dans les fèces dans lequel le ver parasite détruit est une filaire des chiens.  
30  
35
9. Procédé selon la revendication 8, dans lequel l'anticorps est fixé sur une phase qui est non miscible à l'échantillon.
10. Procédé selon la revendication 9, dans lequel la phase est une phase solide.  
40
11. Procédé selon la revendication 8, dans lequel l'anticorps est lié à une fraction détectable.
12. Procédé selon la revendication 11, dans lequel la fraction détectable est une enzyme, une particule colloïdale, un radionucléide ou un fluorophore.  
45
13. Procédé pour détecter si le tube digestif d'un animal est infecté par des ascaris, des ankylostomes, ou des trichures comprenant : l'immobilisation d'un anticorps dirigé contre la fraction soluble dans l'acide trichloroacétique d'une filaire des chiens détruite sur une phase solide, dans laquelle l'anticorps se lie à un antigène d'ascaris, un antigène d'ankylostome, et un antigène de trichure ; l'ajout d'une partie soluble d'un échantillon de selles de l'animal sur la phase solide ; la détection de la liaison d'un antigène de ver parasite à l'anticorps immobilisé, dans laquelle l'antigène de ver parasite est un ou plusieurs parmi un antigène d'ascaris, un antigène d'ankylostome, ou un antigène de trichure, détectant ainsi si l'animal est infecté par un ver parasite.  
50
14. Procédé selon la revendication 13, dans lequel la détection de la liaison de l'antigène de ver parasite à l'anticorps immobilisé comprend la mise en contact de la phase solide avec un anticorps de filaire des chiens conjugué à une marque.  
55
15. Procédé selon la revendication 13, comprenant en outre l'ajout d'un antigène de filaire des chiens conjugué à une

## EP 1 620 725 B1

marque à la partie soluble d'un échantillon de selles de l'animal avant l'ajout à la phase solide de la partie soluble de l'échantillon de selles et la détermination de la présence, l'absence ou la quantité de la liaison de l'antigène marqué à l'anticorps.

- 5     **16.** Procédé selon la revendication 13, comprenant en outre l'essai d'un échantillon de sang du mammifère pour détecter la présence ou l'absence d'un antigène de filaire des chiens dans l'échantillon de sang.
- 10     **17.** Procédé pour détecter la présence ou l'absence d'une infection par un ver parasite intestinal comprenant : (a) la fourniture d'un dispositif de dosage immunologique à écoulement latéral ayant une phase solide ; (b) la fourniture d'un premier anticorps dirigé contre la fraction soluble dans l'acide trichloracétique d'une filaire des chiens détruite ; (c) l'immobilisation du premier anticorps sur la phase solide du dispositif de dosage immunologique ; (d) la fourniture d'un deuxième anticorps marqué ; (e) la fourniture d'une fraction soluble d'un échantillon de selles ; (f) la mise en contact de la fraction soluble de l'échantillon de selles avec le deuxième anticorps marqué ; (g) laisser la fraction soluble de l'échantillon de selles et le deuxième anticorps marqué s'écouler le long du dispositif de dosage immunologique vers le premier anticorps immobilisé ; et (h) la détermination de la présence ou l'absence d'un parasite intestinal choisi parmi une filaire des chiens, un ascaris, un ankylostome ou un trichure, par l'observation de la présence ou l'absence d'un signal dans le voisinage du premier, anticorps immobilisé.
- 15
- 20     **18.** Procédé pour détecter la présence ou l'absence d'une infection par un ver parasite intestinal choisi parmi une filaire des chiens, un ascaris, un ankylostome ou un trichure chez un animal comprenant . (a) le passage d'un échantillon de sang de l'animal sur un dispositif de détection d'antigène de filaire des chiens afin de déterminer la présence ou l'absence de l'antigène de filaire des chiens dans l'échantillon de sang ; et (b) si l'échantillon de sang est négatif pour la présence de l'antigène de filaire des chiens, le passage d'un échantillon de selles provenant du même animal sur un dispositif de détection d'antigène du ver parasite afin de déterminer la présence ou l'absence de l'antigène du ver parasite dans l'échantillon de selles.
- 25

30

35

40

45

50

55

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- US 5266266 A [0017]
- US 5726010 A [0031] [0036]

**Non-patent literature cited in the description**

- *the American Journal of Veterinary Research*, May 1998, vol. 59 (5), 533-537 [0004]
- Database. PREV2003 00526129 [0004]
- *Journal of the American Veterinary Medical Association*, 01 April 1988, vol. 192 (7), 913-916 [0005]
- **Harlow, E. ; D. Lane.** Antibodies: A Laboratory manual. Cold Spring Harbor Laboratory, 1988, 92-286 [0022]
- **Dean.** *Methods Mol. Biol.*, 1998, vol. 80, 23-37 [0024]
- **Dean.** *Methods Mol. Biol.*, 1994, vol. 32, 361-79 [0024]
- **Baileg.** *Methods Mol. Biol.*, 1994, vol. 32, 381-88 [0024]
- **Gullick.** *Methods Mol. Biol.*, 1994, vol. 32, 389-99 [0024]
- **Drenckhahn et al.** *Methods Cell. Biol.*, 1993, vol. 37, 7-56 [0024]
- **Morrison.** *Ann. Rev. Immunol.*, 1992, vol. 10, 239-65 [0024]
- **Wright et al.** *Crit. Rev. Immunol.*, 1992, vol. 12, 125-68 [0024]

专利名称(译)	检测粪便样品中的分析物		
公开(公告)号	<a href="#">EP1620725B1</a>	公开(公告)日	2011-08-03
申请号	EP2004750577	申请日	2004-04-23
[标]申请(专利权)人(译)	艾德克斯实验室公司		
申请(专利权)人(译)	IDEXX实验室, INC.		
当前申请(专利权)人(译)	IDEXX实验室, INC.		
[标]发明人	TONELLI QUENTIN J GROAT RANDALL G MONN MICHAEL P		
发明人	TONELLI, QUENTIN, J. GROAT, RANDALL, G. MONN, MICHAEL, P.		
IPC分类号	G01N33/53		
CPC分类号	G01N33/5308		
优先权	10/424282 2003-04-25 US		
其他公开文献	EP1620725A2		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

一种检测哺乳动物消化道寄生虫感染的方法。该方法包括检测蠕虫抗体与存在于受感染哺乳动物的粪便样品的可溶部分中的蠕虫抗原的结合。

Sample	Microscopic Examination		SNAP® Device Immunoassay Result
	Result	Parasitic Worms Identified	(Visual Examination)
37172	Positive	roundworms	Negative
36986	Positive	hookworms, whipworms	Positive
36814	Positive	whipworms	Negative
37164	Positive	roundworms, hookworms	Positive
37174	Positive	hookworms	Positive
38000	Positive	hookworms	Positive
37138	Positive	hookworms, whipworms	Positive
37186	Positive	hookworms	Positive
37168	Positive	hookworms	Positive
37034	Positive	whipworms	Positive
36707	Positive	roundworms	Positive
37159	Positive	hookworms	Positive
36449	Positive	roundworms	Positive
36528	Negative	none detected	Negative
37100	Negative	none detected	Positive
36438	Negative	none detected	Negative
36409	Negative	none detected	Negative
36206	Positive	hookworms	Positive
37311	Positive	hookworms, whipworms	Positive
37327	Positive	roundworms, hookworms	Positive
37406	Positive	roundworms, hookworms	Positive
37522	Positive	roundworms	Positive
37549	Positive	hookworms	Negative
37532	Positive	hookworms	Negative
37241	Positive	hookworms, whipworms	Positive
37330	Positive	roundworms	Positive